CluenexBristol-Myers Squibb Company BMY
Bristol-Myers Squibb Company scores average on business quality (5.5 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Bristol-Myers Squibb Company does
Bristol-Myers Squibb discovers, develops, and delivers specialty biopharmaceuticals to patients battling serious diseases like cancer and immunological disorders. Hospitals and physicians pay for these prescription therapies through complex global healthcare channels.
- What it does best
Bristol-Myers Squibb excels at generating elite cash flows, printing a free cash flow margin of 34% that sits in the top decile of its sector. This efficiency stems from a specialized drug portfolio that outpaces peers like Pfizer, which posts a free cash flow margin of 17%.
- The main risk
Patent expirations on core revenue drivers threaten top-line stability as generic alternatives erode market share. Without sufficient pipeline replenishment, revenue contraction will directly impair cash generation capabilities.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin hits 35.5% while free cash flow margin reaches 34%, both expanding as high-margin specialty drugs scale. This business model turns revenue into cash efficiently at scale.
Patented drug portfolios lock in healthcare providers and patients behind regulatory barriers. An operating margin in the top quartile of its sector reflects this pricing power, though patent cliffs limit long-term defensibility.
Revenue growth sits in the bottom decile of its sector at -0.2%, showing a stagnant top line that continues to fade against broader healthcare industry expansion.
Debt-to-equity sits at 2.4 while interest coverage is 10x, leaving debt costs manageable. Free cash flow reached $16.7B, getting stronger as operations generate cash efficiently.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
2 sold $437K outside pre-planned sales.
Our sealed record on BMY
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Bristol-Myers Squibb Company scores average on the Cluenex quality check (5.5 of 10), measured against its own industry. Profitability is strong, moat fair, growth slow and financial health fair.
In the last 90 days of SEC Form 4 filings: 2 sold $437K outside pre-planned sales.
Oct 29, 2026.
See BMY today
- Today's verdict on BMY, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Bristol-Myers Squibb Company (BMY)”, https://cluenex.com/stocks/bmy/, data as of Oct 10, 2026.